Cited 2 times in
Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박준용 | - |
dc.date.accessioned | 2020-12-11T07:50:28Z | - |
dc.date.available | 2020-12-11T07:50:28Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180682 | - |
dc.description.abstract | The treatment of multidrug-resistant (MDR) chronic hepatitis B (CHB) is challenging. Herein, we report a multicenter prospective cohort study for the evaluation of tenofovir disoproxil fumarate (TDF)-based therapy for MDR CHB in a real-life setting. The inclusion criteria comprised patients with resistance to more than two nucleos(t)ide analogue (NA) classes and hepatitis B virus (HBV) DNA level of ≥200 IU/mL. The primary end-point was virologic response (VR), defined as undetectable HBV DNA (<20 IU/mL) after 60 months. A total of 236 patients met the inclusion criteria. The mean HBV DNA level was 4.16 ± 1.44 log IU/mL; 26.7% of patients had liver cirrhosis. Before the initiation of TDF, 33.5%, 44.9% and 21.6% of patients had mutations resistant to L-NA + adefovir, L-NA + entecavir (ETV) and L-NA + adefovir + ETV, respectively. A total of 184 patients received TDF-based combination therapy [TDF + ETV (n = 178) or TDF + L-NA (n = 6)], and 52 patients received TDF monotherapy. In the entire cohort, the VR rates were 77.2%, 89.9% and 92.2% at 12, 36 and 60 months, respectively. The VR rates were not significantly different between the combination therapy and the monotherapy group after 12 (76.2% vs 80.4%, P = .533), 36 (89.8% vs 90.3%, P = 1.000) or 60 (92.9% vs 87.5%, P = .499) months. Also, there was no significant difference in the cumulative VR rates for 5 years between the treatment groups (P = .910). Newly developed antiviral resistance was not observed. TDF-based therapy was effective for the treatment of MDR CHB. The efficacy of TDF monotherapy was not different from that of the TDF-based combination therapy. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Scientific Publications | - |
dc.relation.isPartOf | JOURNAL OF VIRAL HEPATITIS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyung Joon Yim | - |
dc.contributor.googleauthor | Sang Jun Suh | - |
dc.contributor.googleauthor | Young Kul Jung | - |
dc.contributor.googleauthor | Seong Gyu Hwang | - |
dc.contributor.googleauthor | Yeon Seok Seo | - |
dc.contributor.googleauthor | Soon Ho Um | - |
dc.contributor.googleauthor | Sae Hwan Lee | - |
dc.contributor.googleauthor | Young Seok Kim | - |
dc.contributor.googleauthor | Jae Young Jang | - |
dc.contributor.googleauthor | In Hee Kim | - |
dc.contributor.googleauthor | Hyoung Su Kim | - |
dc.contributor.googleauthor | Ji Hoon Kim | - |
dc.contributor.googleauthor | Young Sun Lee | - |
dc.contributor.googleauthor | Eileen L Yoon | - |
dc.contributor.googleauthor | Myeong Jun Song | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.identifier.doi | 10.1111/jvh.13363 | - |
dc.contributor.localId | A01675 | - |
dc.relation.journalcode | J01928 | - |
dc.identifier.eissn | 1365-2893 | - |
dc.identifier.pmid | 32706461 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/jvh.13363 | - |
dc.subject.keyword | chronic hepatitis B | - |
dc.subject.keyword | multidrug resistance | - |
dc.subject.keyword | tenofovir | - |
dc.subject.keyword | therapy | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.citation.volume | 27 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1306 | - |
dc.citation.endPage | 1318 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VIRAL HEPATITIS, Vol.27(12) : 1306-1318, 2020-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.